Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review  by Zhu, Y. et al.
Osteoarthritis and Cartilage 21 (2013) 1627e1637ReviewBasic science and clinical application of platelet-rich plasma
for cartilage defects and osteoarthritis: a review
Y. Zhu, M. Yuan, H.Y. Meng, A.Y. Wang, Q.Y. Guo, Y. Wang, J. Peng*
Institute of Orthopedics, Chinese PLA General Hospital, Fuxing 28# Road, Beijing 100853, Chinaa r t i c l e i n f o
Article history:
Received 12 June 2013
Accepted 30 July 2013
Keywords:
Platelet-rich plasma
Cartilage defects
OsteoarthritisAbbreviations: EGF, epidermal growth factor.
* Address correspondence and reprint requests to:
dics, Chinese PLA General Hospital, Fuxing 2
Tel: 86 13910060749.
E-mail addresses: pengjdxx@126.com, pengjiang3
1063-4584/$ e see front matter  2013 Osteoarthriti
http://dx.doi.org/10.1016/j.joca.2013.07.017s u m m a r y
Cartilage defects (CDs) and the most common joint disease, osteoarthritis (OA), are characterized by
degeneration of the articular cartilage that ultimately leads to joint destruction. Current treatment
strategies are inadequate: none results in restoration of fully functional hyaline cartilage, for uncertain
long-term prognosis. Tissue engineering of cartilage with auto-cartilage cells or appropriate mesen-
chymal stem cell (MSC)-derived cartilage cells is currently being investigated to search for new therapies.
Platelet-rich plasma (PRP), an autologous source of factors obtained by centrifugation, possesses various
functions. For culture of MSCs and cartilage cells, it might be substituted for fetal bovine serum (FBS)
with high efﬁciency and safety. It enhances the regeneration of cartilage cells when added to cartilage
tissue engineering constructs for repairing CDs and as regenerative injection therapy for OA. But chal-
lenges also remain. Some of the growth factors (GFs) present in PRP have negative effects on the OA joint.
It is therefore unlikely that a mix of GFs some of which have negative effects in the OA joint, as present in
PRP, will be of beneﬁt in OA. Future directions of PRP application may concentrate on seeking an
appropriate and innocuous agent like anti-VEGF antibody that can modulate and control the effect of PRP.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage damage is usually caused by sports injuries or
accidental trauma and aging. It regularly progresses tomore serious
joint disorders such as osteoarthritis (OA), necrosis of subchondral
bone tissue or arthritis. An estimated 15% of the world’s population
have joint diseases; more than 39 million people in the European
Union andmore than 20million Americans have OA. By 2020, these
numbers will probably be doubled1.
After traumatic or pathological injury, hyaline articular cartilage,
the load-bearing tissue of joint, has limited or no intrinsic capacity
for repair capacity, and even minor lesions or injuries may lead to
progressive damage and joint degeneration.
OA is a chronic degenerative joint disease characterized by
progressive destruction of articular cartilage, thinning and eventual
wearing of articular cartilage, thus resulting in painful, limited joint
movement. The degeneration of articular cartilage, mainly due toJ. Peng, Institute of Orthope-
8# Road, Beijing, China.
01@126.com (J. Peng).
s Research Society International. Pchanges in the activity of chondrocytes in favor of catabolic activity,
which also involves other joint tissues, as alterations of the
meniscus, sclerosis and edema in the underlying subchondral bone
as well as intermittent inﬂammation of synovium.
Current treatments for articular cartilage damage, such as sur-
gical intervention (microfracture, osteochondral auto- or allo-
grafts), to repair articular cartilage are less than satisfactory and
rarely restore full function. To obtain sufﬁcient chondrocytes for
therapy, the required in vitro expansion usually induces cartilage
cell dedifferentiation. Tissue engineering-based cartilage repair has
been pursued to provide more functional biological tissue. The
chondrocytes are taken from non-weight-bearing parts of intact
joint areas and expanded in cell culture, then transplanted into the
defective areas of the affected joints. Clinical trials of autologous
chondrocyte implantation (ACI) have shown promise2.
Multipotent adult mesenchymal stem cells (MSCs) can differ-
entiate into cells of the chondrogenic lineage and are isolated from
a wide variety of tissue sources; they are easy to isolate without
signiﬁcant donor-site morbidity and are easier to expand in vitro
than chondrocytes3. These cells are also used for cartilage tissue
engineering and chronic degenerative disorders and to prevent
cartilage degradation in OA because of their trophic/regenerative
potential. This therapeutic method needs a large quantity of cells to
obtain enough cartilage cells or MSC-derived cartilage cells. Mostublished by Elsevier Ltd. All rights reserved.
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(FBS/FCS) as a growth factor (GF) supplement, which is a potential
source of undesired xenogeneic pathogens and raises concerns
when used in clinical-grade preparations. A substitute for FBS/FCS
is needed.
The ﬁrst descriptions of the development and use of platelet-
rich plasma (PRP) were in the early 1990s, when science focused
on developing new “biological glues”. PRP has been classically
described as “a volume of plasma that has a platelet count above
baseline”. This deﬁnition would suggest a pure mixture of plasma
(the acellular, liquid portion of blood that contains proteins for
clotting and other bioactive molecules that play a signiﬁcant role in
wound repair) and platelets (and their associated GFs and cyto-
kines). However, the generic term “PRP” has recently expanded to
include a variety of ﬁnal products. Tomore precisely delineate these
products based on their leukocyte and ﬁbrin content, they have
been called pure PRP, leukocyte-rich PRP, pure platelet-rich ﬁbrin,
and leukocyte- and platelet-rich ﬁbrin4. The terms “platelet-rich
concentrate” and “platelet concentrate” are also used for PRP.
Another platelet product is human platelet lysate (HPL).
Here, we discuss the basic science and applications of PRP and
analogue products in cartilage defects (CDs) and OA.
Creating PRP
PRP is prepared by withdrawing peripheral blood and by
centrifugation to obtain a highly concentrated sample of platelets.
The platelets undergo degranulation to release GFs with healing
properties. The plasma contains cytokines, thrombin, and other
GFs, with inherent biological and adhesive properties.
The ﬁrst report of PRP preparationwas in the 1970s5. A few years
later, attention was drawn to gravity forces and times of centrifu-
gation to separate whole blood, which is crucial for platelet counts
and volume. Then the focus was on platelet content of the PRP with
an objective standard. With the platelet activation method pro-
posed in the last decade, study of the various GFs released from
activated PRP became popular, and preparation was diversiﬁed.
Although peripheral venous blood factors inﬂuence the contents of
the ﬁnal PRP product, platelet activation was conﬁrmed to be a key
point in platelet counts and GFs: how to obtain more platelet
counts with a small volume of PRP, how to improve the concen-
tration of GFs released by PRP and which methods can bring about
sustained release of GFs6.
The most basic method to prepare PRP is centrifugation, divided
into a one-step and two-step-centrifugation protocol (Fig. 1). The
effect of separation by these two methods is still controversial.
According to discarded and retained components, PRP is divided
into different categories. The increase in commercial applications
led to the development of PRP kits. Whether PRP is prepared by
manual centrifugation or by use of kits, platelet concentration isFig. 1. Two-step-centrifugation protocol. The ﬁrst centrifugation separate out the red blood
released from platelet products.signiﬁcantly higher than in whole blood. However, the concentra-
tion of platelets obtained by each method still differs. In addition,
platelet content is affected by the donor’s gender (higher with fe-
male than male plasma) and personal physical aspects but not age.
In contrast, the GF content is not inﬂuenced by age or gender. Even
the content might differ in the same individual with use of different
systems or different manufacturers.
The GFs will release after exogenous or endogenous activation.
Different methods of activating PRP probably affect the concen-
tration of GFs. PRPs are commonly activated by calcium chloride,
thrombin, chitosan and batroxobin. Calcium chloride and thrombin
activation are the twomost commonmethods; 5% calcium chloride
treatment for 19 min produces the most effective PRP, which have
properties for soft-tissue adhesion7. Chitosan can be used instead of
thrombin because it enhances aggregation, adhesion and expres-
sion of alpha-granule membrane glycoprotein. Furthermore, scaf-
folds by freeze-drying PRP with chitosan gel can produce sustained
release of GFs6. This potential contributes to the durability of GFs in
clinical and experimental studies. As well as platelet content,
concentration of GFs differs between each person.
Bioactivity of PRP
The platelets in PRP range from 2 to 3 mm; proteomic studies
have shown that platelets contain more than 800 proteins with
numerous post-translational modiﬁcations8, such as phosphoryla-
tion, for more than 1,500 protein-based bioactive factors. The
physiologic actions of some of the proteins have been studied,
including GFs, peptide hormones, and chemoattractants for mac-
rophages, neutrophils, stem cells and several hundred other pro-
teins, such as ﬁbrinogen and ﬁbrin. Fibrin acts as a provisional
scaffold for stem or primary cell migration and differentiation and
functions as a biological glue. Platelets also store proteins with
antibacterial and fungicidal effects, coagulation factors, and mem-
brane glycoproteins that inﬂuence inﬂammation by increasing the
synthesis of interleukins (ILs) and chemokines. Dense granules in
platelets also store and release adenoside diphosphate (ADP),
adenoside triphosphate, calcium ions, histamine, serotonin, and
dopamine, which are active in tissue homeostasis.
Platelets actively participate in healing processes by delivering a
broad spectrum of GFs and other active molecules (e.g., chemo-
kines, arachidonic acid metabolites, extracellular matrix (ECM)
proteins, nucleotides, ascorbic acid) to the injured site by exocytosis
following adhesion or stimulation by thrombin and other strong
stimuli-like calcium. GFs secreted by platelets include platelet-
derived growth factor (PDGF), epidermal growth factor (EGF),
insulin-like growth factor (IGF-I), transforming growth factor b-I
(TGFb-I), vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF) and basic ﬁbroblast growth factor (bFGF)9. This
wide variety of GFs contribute to multifaceted roles of PRP,cells and the second centrifugation to concentrate the platelets. Growth factors were
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vessel remodeling, angiogenesis, inﬂammation, coagulation and
cell differentiation10. These substances act in synergy on local cells
inducing speciﬁc responses: promotion of proliferation, cell
migration, and synthesis of ECM proteins including collagen, even
changing the cell phenotype and arrangement11.
Both native and exogenous molecules such as calcium,
thrombin, ADP, collagen, and magnesium can activate platelets.
Once platelets are activated, an initial burst of GF release is fol-
lowed by further sustained release, a 3- to 5-fold increase as
compared with baseline. Platelet activation increases levels of anti-
inﬂammatory cytokines because of the presence of hepatocyte GF.
These GFs have a particular function in bone remodeling and
wound healing as well as stimulation of cartilage matrix synthesis
and affect catabolic cytokines such as IL-1, IL-4, IGF-1, osteogenetic
protein (OP)-1, FGF, TGFs and PDGF12.
TGF-b is widely considered a promoter for chondrocyte anabo-
lism in vitro (enhancing matrix production, cell proliferation,
osteochondrogenic differentiation), and intra-articular injections
help increase bone formation in vivo. It decreases type I collagen
(col-I) gene expression, which simultaneously upregulates type II
collagen (col-II) and aggrecan gene expression. TGF-b cooperates
with bFGF to induce the migration and supplementation of bone-
marrow stromal cells (BMSCs) toward the site of injury. It also
stimulated cell homing, proliferation and chondrogenic differenti-
ation13; sustained release of TGF-b is needed in the entire process of
differentiation into cartilage. TGF-b facilitates cell proliferation by
changing cell morphologic features. Therefore, both the quantita-
tive and qualitative components of PRP are effective in mimicking
the natural processes of soft-tissue wounding. In initiating and
facilitating the formation of cartilage, PRP may be a potential
candidate for inducing chondrogenesis and sustaining chondrocyte
phenotype in vitro and in vivo.
Some GFs released from PRP may inﬂuence chondrocyte
phenotype or differentiation. As stated above, the platelet count
and leukocyte count in PRP may differ between different prepara-
tions from the same individual. TGF-b is a chondrocyte preserver by
ﬁrst regulating sulfation of glycosaminoglycans (GAGs), but along
with elevating TGF-b1 activity has been suggested to be associated
with elevated bone mass and OA14. Because of hypertrophia of
articular chondrocytes in the proliferation process triggered by
TGF-b1, levels of cartilage marker proteins aggrecan and col-II
gradually disappeared15.
From the bioactivity of PRP, the extensive application of PRP in
different ﬁelds, including bone, ligaments, rotator cuff repair, and
skin damage, is also used for the reduction of postoperative com-
plications, subjective pain and improving tissue healing16. In the
numerous GFs of PRP release, part of them have a conducive to
maintain the phenotype of chondrocytes, others are not, how to use
the needed side is the direction of our future study.
Application of PRP for cartilage cell culture (Table Ia)
Articular cartilage, unlike most tissues, has special nutritional
requirements and is extremely difﬁcult to repair spontaneously
after injury because of lack of blood supply. With the boom in
tissue engineering technology, treatment with cultured autolo-
gous cartilage cells and engineered tissue for repairing the artic-
ular CDs has been effective. Obtaining sufﬁcient chondrocyte
numbers for therapy requires in vitro expansion. The standard
methods for cartilage cell expansion involve culture medium with
FBS or serum-free medium. FBS may contain exon-antigen and
cause immune-related problems, and serum-free medium is
expensive, so a substitution for FBS and serum-free medium is
needed. Studies of cultivating chondrocytes in PRP or humanplatelet supernatant showed the promotion of cell proliferation in
monolayer culture and with use of a 3-D environment such as
alginate microsphere (Fig. 2); it also increased the expression of
GAG and col-II (Table I). The use of PRP even slightly enhanced
mitogenic stimulation as compared with FBS. However, some re-
ports indicated that PRP activated only chondrocyte proliferation
but not differentiation. The mRNA levels of col-II, aggrecan and
bone morphogenetic protein 2 were reduced, but col-I expression
was considerably induced17,18. If PRP can maintain the morphology
and characterization was not clear, dedifferentiation of chon-
drocytes was still happened. These different results may due to
different preparation of PRP and the different GFs in the PRP from
different individuals. The standard methods for preparation of PRP
need further study.
PRP for MSC differentiation to cartilage cells in vitro (Table Ib)
MSCs are multipotent stem cells that can be obtained by
numerous approaches. They have multi-differentiation potential,
especially high chondrogenic differentiation potential and rapid
growth rate, which can be used effectively in damage repair and
tissue engineering. Transplanted MSCs seeded with col-I hydrogels
were ﬁrst used to repair CDs in human OA knees. In vitro, MSCs can
be induced in different cell type directions by use of different in-
duction media and possess potent immunomodulatory and anti-
inﬂammatory effects19. PRP added to the culture medium retains
the immune-regulatory effect of MSCs. It can decrease alloantigen-
induced cytotoxic activity, favors differentiation of CD4þ T-cell
subsets expressing a Treg phenotype and increases early secretion
of IL-10 as well as induces a striking augmentation of IL-6 pro-
duction. PRP in medium also showed resistance to spontaneous
transformation into tumor cells as demonstrated by molecular
karyotyping and maintenance of normal morphology/phenotype
after prolonged in vitro culture20.
PRP stimulates adhesion migration and proliferation of stem
cells and also enhances chondrogenic differentiation. It signiﬁ-
cantly stimulates chondrocyte GAG synthesis and tends to increase
col-II level. PRP was more reproducibly efﬁcient than FBS in sup-
porting MSC outgrowth. This may be related to the GFs released
from PRP.
However, some reports expressed inconclusive results. A tendon
bone healing experiment after ACL reconstruction suggests that
60% PRP has good biocompatibility and osteoinductive capacity21.
Also, Stromal stem cells cultured in 10% PRP show the high prolif-
eration rate and cells return to their regular proliferation rate and
osteochondral potential after PRP is withdraw22.
PRP for OA in animal model (Table IIa)
OA is widely considered an age-related degenerative disorder
often resulting in chondral lesions, which presents as cartilage
wearing away so that the underlying bones are exposed and rub
together painfully. Cartilage lacks innate abilities for a sufﬁcient
healing response. Thus, damaged tissue is not replaced with func-
tional tissue. Histology shows the inﬂammatory reaction in the
affected joints. OA progression is slow and may occur over 15e30
years. Viscosupplementations, such as intra-articular hyaluronic
acid (HA), oral glucosamine, or chondroitin-sulfate, are commonly
used as supportive treatment. However, the usefulness remains
controversial given the paucity of supporting evidence. Trying to
prevent cartilage ECM degenerating is effective in defending OA
progress. For economic and methodological considerations, the use
of bioactive agents such as recombined GFs in an appropriate car-
rier to help the defect heal itself has been of interest23. Recently,
experimental study has identiﬁed the effects of PRP on OA in
Table I
PRP application in vitro
Cell type Classiﬁcation of PRP58 PRP application to culture Outcome Reference
a. PRP for chondrocyte culture
Human chondrocytes P2-x-NA Cells seeded on gelatin microcarriers
sealed with PRP
Improve cell proliferation and ECM synthetize
and maintain cell phenotype
59
Porcine chondrocytes P3-x-Aa 10% PRP release in serum-free medium Improve cell proliferation and matrix biosynthesis,
PG and collagen synthesis
60
Human chondrocytes P4-B In mono- and 3-D cultures Improve cell proliferation and ECM synthetize and
maintain cell phenotype
61
New Zealand white rabbit
chondrocytes
P4-NA 20% PRP in DMEM Improve cell proliferation and increase aggrecan,
BMP-2, BMP7, col-II expression in the long-term
62
Japanese white rabbit
chondrocytes
P4-x-NA 3% PRP with alginate beads Increase chondrocyte GAG synthesis and maintain
cell phenotype.
28
Human articular chondrocytes NA-x-Bb In mono- and 3-D cultures Improve chondrocyte proliferation but reduce
type II collagen, aggrecan and BMP-2
17
Bovine articular chondrocytes NA-x-Bb In mono- and 3-D cultures Improve chondrocyte proliferation but reduce
type II collagen, increase type I collagen
18
b. PRP for MSC culture
Human mesenchymal
stem cell (HMSC)
P2-Aa 10% PRP in DMEM Improve cell proliferation and induce
chondrogenesis
63
BM-HMSCs NAeNA 10% HPL Improve cell proliferation 64
BM-HMSCs P3-NA 5% HPL Improve cell proliferation and decrease
alloantigen-induced cytotoxic activity
20
BM-HMSCs P3eB 10% HPL Improve cell proliferation, preserve phenotype and
differentiation capacity
65,66
BM-HMSCs P2-x-Bb 10% PRP Improve cell proliferation and migration 67
Human subchondral
progenitor cells
P4-NA-B 5% PRP Improve cell proliferation and induce chondrogenesis 68
Human adipose
tissue-derived MSCs
P4-x-NA 10% PRP Improve cell proliferation, preserves differentiation
capacity and immunophenotype
69
Mouse muscle-derived
stem cell (MDSC)
P3-x-NA 10% PRP Improve cell proliferation and upregulate
type II collagen
70
Nude rats MDSC P2-NA Pellet culture added PRP combined with
a VEGF antagonist and BMP-4
Increase type II collagen 24
Sheep MDSC NA-x-NA High-density micromass culture in PRP Improve cell proliferation 71
Human BMSC P3-NA Pellet culture with 5% HPL Increased cell proliferation formed evident and
clear cartilage
72
P1, P2, P3, P4 represent platelet concentrations (platelets/mL): P1, baseline levels; P2, >baseline levels to 750,000; P3, 750,000e1,250,000; and P4, >1,250,000. Endogenous
activation has no designation. If an exogenous external activator is used, it is documentedwith an x. Total leukocyte content in buffy coat is identiﬁed as A,>baseline level, or B,
baseline levels; neutrophil count is identiﬁed as a, >baseline level, or b, baseline levels. NA, not applicable.
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an optimal candidate agent for OA because of its milieu of GFs, it is
easily obtained and prepared. The effects of PRP include few
postoperative complications, alleviating pain, antimicrobial effects
and anti-inﬂammatory effects30. Its initial inhibition of macrophage
proliferation may explain this phenomenon.
In an OA model induced by formalin, collagenase, or anterior
cruciate ligament transfection, treatment with PRP/gelatin hydro-
gel injected in knee joints increased mRNA expression of proteo-
glycan core protein in the articular cartilage and decreased
chondrocyte apoptosis24 and suppressed progression of OA28. The
effects were related to severity of OA27. PRP combined with stemFig. 2. Chondrocytes ecells injected into knees increased col-II content and decreased
chondrocyte apoptosis24 The most common PRP application is in-
jection, which avoids the adverse effects of surgery.
In addition, with osteoarthritic chondrocytes cultured in the
presence of IL-1 to mimic the osteoarthritic environment, PRP can
diminished multiple inﬂammatory IL-1 mediated effects. It has
analgesic, antibacterial, anti-inﬂammatory activity; balances joint
angiogenesis, coagulation and hemostasis; increases GAG level; and
stimulates chondrocyte synthesis cartilage matrix, for stem or
primary cell migration, differentiation, as well as wound healing.
PRP may become an attractive candidate to remedy and protect
against cartilage degeneration in OA.xpansion in vitro.
Table II
PRP application in animal models
Animal model (symptom) Classiﬁcation
of PRP58
PRP application to joint Study outcome: effect because of PRP Reference
a. OA
Male New Zealand white
rabbits (OA)
P4-NA PRP injection Higher gross morphologic and histologic scores,
stimulate cell proliferation and matrix metabolism
27
Nude rats (OA) P2-NA PRP þ MDSC injected into knee Increase type II collagen content and decrease
chondrocyte apoptosis
24
Wistar rats (OA) P3-x-NA PRP gel injection Moderate degeneration of cartilage layer 25
Japanese white rabbits (OA) P4-x-NA PRP þ gelatin hydrogel
microsphere injection
Lower gross morphological OA scores, suppressed
progression of OA
28
b. CD
Sheep (full-thickness CD) P2-x-NA Microfracture þ PRP gel Healthy surrounding cartilage showed intense cell
proliferation with formation of cell clusters
31
P2-NA Microfracture þ Liquid PRP injection A great amount of chondrocyte-like cells well
organized in columns
Rabbits (full-thickness CD) P4-x-NA Microfracture þ PRP þ polylacticglycolic
acid (PLGA) implantation
Induced regeneration of cartilage and subchondral
bone into and around the defect
26
New Zealand white rabbits
(full-thickness CD)
P4-Bb PRP þ bilayer collagen scaffold Forms cartilage tissues, produces more GAGs 29
New Zealand white rabbits
(osteochondral defect)
P4-x-Bb MDSC þ PRP Better gross appearance and histological and
immuno-histochemical characteristics, higher
cartilage-speciﬁc gene and protein expression
32
ADSC þ PRP Functional chondrocytes secrete cartilaginous matrix
New Zealand rabbits (CD) NA-x-NA Injection autologous cell-PRP composite Good macroscopic result, forms mature and
homogeneous cartilage with more collagen PG and GAG
73
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CDs caused by trauma, acute injury in sports or any other
movements forms shaped and regular gaps in cartilage. Such
defects can be divided into three depth categories: partial thick-
ness defects, with the defect entirely contained in the cartilage
layer; full-thickness defects, with the defect extending down to
but not into the subchondral bone; and osteochondral defects
that extend into the subchondral bone. PRP for these three types
also can be divided into three modalities: (1) acellular repair
technology, including PRP injection and inﬁltration or PRP
with polylactic/glycolic acid copolymer polylactic acid-coglycolic
acid (PLGA) scaffolds26; (2) PRP with cells, including chon-
drocytes or MSCs; and (3) cell-based tissue engineering, including
cells seeded with PRP gel or on PLGA scaffolds, or microfracture
and matrix-associated autologous chondrocyte transplantation
(MACT) with PRP. PRP enhances the morphological stability of the
constructs, maintains chondrocyte phenotypes and induces
chondrogenesis,
PRP added to a cartilage ECM scaffold combined with micro-
fractures to treat chondral defects improved mechanical and
biochemical quality of repaired tissue31. Comparison of the
chondrogenic differentiation ability of BMSCs and adipose-
derived stem cells (ADSCs) seeded in a PRP scaffold to repair
rabbit CDs revealed that a PRP-derived 3-D scaffold has the ca-
pacity for endogenous GF release and induces both BMSC and
ADSC proliferation and expression of cartilage marker genes and
proteins. Cartilage differentiation was better with BMSCs than
ADSCs in vitro, but both repaired CDs in rabbit32,33. Although PRP
promote bone reconstruction and mature in vitro34 and some-
times can be found highly amorphous cartilaginous repair tissue
and poorly spatially organized underlying bone tissue35, even a
dissatisﬁed results on cartilage repair in sheep models31, PRP still
give us highly promising. The restriction of repair has been found
in PRP alone medium due to angiogenic factors released from
PRP. So they use sFlt1 (an angiogenic antagonist) to block the
angiogenesis and got the ideal result24. In conclusion, the envi-
ronment of healing site and GFs stimuli are both important to
tissue repair.PRP for clinical application in OA (Table IIIa)
The healing process of OA comprises three phases: (1) inﬂam-
mation, (2) cell proliferation, and (3) remodeling. Regenerative
therapy involves injecting a small volume of solution into multiple
sites of painful ligaments and tendons and adjacent joint spaces to
reduce pain and promote tissue repair and growth [Fig. 3(b)]. PRP
was designed for this purpose. It theoretically augments tissue
healing through the natural healing cascade. GFs are released from
the granules of platelets and induce chemotaxis, cell migration,
angiogenesis, proliferation, differentiation, and matrix production.
PRP also enhances HA secretion and increases release of angiogenic
GFs33,36.
Kon et al. ﬁrst reported on intra-articular PRP injections at 21-
day intervals to 115 osteoarthritic knees, for a total of three sets
of injections. International Knee Documentation Committee (IKDC)
scores demonstrated statistically signiﬁcant improvement at 6- and
12-month follow-up as compared with at baseline37. The authors
studied PRP vs HA injections in 150 patients, with PRP treatment
giving better results than HA in reducing pain and symptoms and
recovering articular function38. As well, 2-year follow-up of 90 of
181 patients39 revealed the long-term PRP effect in treating knee
degeneration. The same results were found in recent studies40,41. In
30 cases, PRP was successful at week 542. PRP is safe and effective
for treatment of knee OA43,44. More promising results are shown for
PRP use in younger than older patients, and milder than more se-
vere cases had better outcomes and longer-lasting results. HA as a
scaffold combined with PRP showed a durable property and repair
of hyaline cartilage45.
PRP injection was ﬁrst proposed by Sanchez et al. to improve
symptoms and accelerate healing in nontraumatic avulsion frac-
tures of the articular cartilage in soccer players46. As a promising
way to treat degenerative cartilage lesions (DCL) without surgery,
research in this ﬁeld is popular. Preliminary results of 100 patients
indicated that PRP injection is safe and has potential to reduce pain
and improve knee function37. A 2-year follow-up clinical trial of
intra-articular injection of PRP in the knee also found the same
results and showed improved quality of life, especially in young
males39. Similar results were conﬁrmed in recent studies47,48.
Table III
PRP application in the clinic
Symptom Cases Classiﬁcation
of PRP58
Treatment/procedure Time Outcome Reference
a. OA
OA 261 P2-x-Bb 3 injections of PRP (5.0 mL, 2-week intervals) 3 and 6 months A signiﬁcant improvement in pain, stiffness, function,
and the Lequesne Index
74
DCL/OA 181 P4-x-NA 3 PRP lesion site injections (5.0 mL, 21 day intervals) 1 and 2 years IKDC objective score decreased to 59%; IKDC subjective
score decreased to 51
39
OA 134 NAeNA 6 injections of PRP (2.0 mL, twice a week) 7, 13 and 26 weeks WOMAC subscale scores largely reduced, decreased
VAS score,
improved German Orthokine Osteoarthritis Trial (GOAT),
KOOS and knee society clinical rating scale (KSCRS).
75
DCL/OA 72 P4-x-A 3 PRP lesion site injections (5.0 mL, 21 day intervals) 2,6 and 12 months Level: II. Improved IKDC subjective score and EQ-VAS 47
KellgreneLawrence
grade I-III OA
65 P3-Aa PRP injection (3.0 mL) 1, 3, 6, 9, and 12 months Improved IKDC score and VAS score 76
OA 60 P3eB Intra-articular injections (3.0 mL) 3 and 6 months Decreased NRS score and WOMAC scores decreased slower 40
Degenerative joint 54 P3-A 3 PRP injections (5.0 mL, weekly injections) 2, 6, and 12 months IKDC subjective score increased to 64.9  16.8 at 12 months;
Tegner score improved to 3.8  1.3 at 12 months
43
DCL/OA 50 P4-x-NA 3 autologous PRP intra-articular injections
(5.0 mL, 14 day intervals)
2 and 6 months Level: II. Longer efﬁcacy, reducing pain and symptoms and
recovering articular function
38
OA 47 P1-x-B PGA-hyaluronan scaffold þ PRP gel þ ﬁbrin-like glue 3, 6, 9, 12 months Level: IV. Improved median KOOS pain subcategory and
symptom subcategory
45
OA 40 NA-x-B PRP injection (6.0 mL, 1e2 weeks intervals) 6e7 weeks and at 6 months WOMAC scores decreased slower, decreased VAS score 77
OA 33 P4-x-NA PRP þ MSCs injection (3.0 mL) 3 months, 1 year and
24.3 months
Level: IV. WOMAC scores decreased slower, improved
Lysholm scores, changed VAS 2.0  1.1. MRI score improved
to 21.7 points.
78
Knee OA 30 P2eB PRP injection (6e8 cc, weekly injections) 5 weeks WOMAC scores decreased slower 42
Arthritis and degenerative
joint disease
27 P3-x-NA 3 PRP intra-articular inﬁltration
(5.0 mL, weekly injections)
6 months Decrease NRS score and improve WOMAC scores 79
Knee OA 25 P2-A 2 autologous PRP intra-articular inﬁltration
(4.0 mL, 1 month intervals)
6 and 12 months Improved the KOOS score 80
Early OA 22 P2-NA-Bb Intra-articular injections (6.0 mL) 1 week, and 1, 3, 6, and
12 months
Improved WOMAC score and decrease VAS scores 48
Knee OA 14 P4-x-Aa 3 PRP injections (6.0 mL, at 4 weeks intervals) 2, 5, 11, 18 and 52 weeks VAS showed many improvements, reduced pain. 44
b. CD
Osteochondral patellar
lesions
5 NA-NA-Aa Microfracture þ PRP gel beneath the
collagen I/III membrane
2 years Level: IV. MOCART score remains stable in 2 years 81
Osteochondral lesions 23 NA-x-Bb Autologous cell concentrate þ PRP gel 24, 36, 48 months Improved AOFAS score, hyaline cartilage in 4 years 82
26 2 mL of bone marrow concentrateþ1.0 mL
PRP gel (PRP-ﬁbrin)
Full-thickness CD 5 P1-x-B PRP gel þ PGA-hyaluronan scaffold 3, 6, 9, 12 months Level: IV. Improved median KOOS pain subcategory
and symptom subcategory
45
Osteochondral lesions 25 P2-x-Bb 2 mL bone marrow concentrate and
with 1 mL PR-ﬁbrin glue
12, 36, 130 months Improved AOFAS score, highlighted hyaline cartilage
in biopsy specimens
51
Osteochondral lesions 5 NA-x-Bb 2 mL bone-marrow concentrate and
with 1 mL PR-ﬁbrin glue
6, 12, 18, and 24 months Improved AOFAS score, PG replace collagen, increased
type I and type II collagen
83
Osteochondral lesions 20 NA-x-Bb 2 mL bone-marrow concentrate and
with 1 mL PR-ﬁbrin glue
2 years Improved AOFAS score, good T2-mapping sequence
result and MOCART score
84
Full-thickness CD 5 P3-NA Bone-marrow mesenchymal stem cells
(BM-MSCs) þ PR-ﬁbrin glue
6, 12 months Level: IV. Improved Lysholm and RHSSK scores 49
T2-mapping gives information about the interaction between water molecules and the collagen network within cartilage and represents a fascinating non-invasive diagnostic technique for the qualitative evaluation of
cartilaginous tissue. MOCART score is using different variables to describe the constitution of the cartilage repair tissue and the surrounding structures. WOMAC Score: Knee Injury and Osteopaedic Outcome Score. IKDC Score:
International Knee Documentation Committee Score. VAS Score: Visual Analogue Scale Score. KOOS Score: Knee injury and Osteoarthritis Outcome Score. AOFAS: American Orthopaedic Foot and Ankle Society. RHSSK Score:
Revised Hospital for Special Surgery Knee Score.
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Fig. 3. PRP clinic application. PRP has been wildly used in CDs (a1, a2, a3) and OA (b) now. Autologous stem cells from bone marrow through microfracture with PRP gel (PR-ﬁbrin
glue) was frequently be used in partial thickness defects (a1 right ﬁgure) and full-thickness defects (a2 right ﬁgure). Cultured autologous chondrocyte or MSCs using PRP gel is also
utilized for repairing in partial thickness defects (a1 left ﬁgure) and full-thickness defects (a2 left ﬁgure). As for the therapies of osteochondral defects, PRP gel with scaffold (a3 left
ﬁgure) and bone marrow concentrate injection with PR-ﬁbrin glue (a3 right ﬁgure) were used in most cases. Comparing the therapies of CD, OA has much less choices for its
complexity. Reports showed that injection (or inﬁltration) therapies are the most common choice (b).
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to accelerate physiologic healing and a return to function. PRP is
used for hemostasis and for total joint arthroplasty for OA. It
can be used intraoperatively in conjunction with a ﬁbrin sealant
or a gel and even alone during total knee arthoplasty. PRP is
used for knee and hip joints. Its use is associated with reduced
inﬂammation, pain relief, improved function, and possible carti-
lage regeneration. The persistence of the beneﬁcial effects re-
mains to be evaluated. Strong evidence from well-designed
clinical trials to support PRP therapy for OA of the knee is needed.
Different PRP products might be more or less appropriate to treat
different types of tissues, and pathologies also remain too many
disputes.PRP for CDs in the clinic (Table IIIb)
PRP has been found being a good carrier and facilitator for
cartilage tissue engineering by reducing inﬂammation and
improving cartilage repair. Especially, it helps stem cells differen-
tiate to cartilage and bone in osteochondral defects [Fig. 3(a)]. MSCs
seeded with PRP improving the repair of articular CDs was ﬁrst
proposed by Haleem et al.49.
In recent years, acellular repair technology has used PRP with
scaffolds such as HA, hydrogel or PRP gel, the solid state of PRP, to
imitate the native environment. A polyglycolic acid (PGA)-hyalur-
onan scaffold with PRP added in drilling can lead to the formation
of hyaline-like cartilage after 1 year45.
Table IV
Dual character of PRP use for cartilage repair and OA in clinical
The strong facts for the use
of PRP in clinical
The poor support for the use
of PRP in clinical
Improve WOMAC, AOFAS and
VAS scores.
Increased type I collagen which
not exist in hyaline cartilage.
Symptomatic relief in early OA and
improve clinical outcome85.
Produce ﬁbrous cartilage.
Inﬂammation reduction. Stimulates angiogenesis86
Y. Zhu et al. / Osteoarthritis and Cartilage 21 (2013) 1627e16371634PRP with a collagen scaffold in tissue engineering can improve
bone-marroweinitiated cartilage repair and stimulate the repair of
large articular cartilage in animal models29. Also, hydrogel com-
bined with chondrocytes and PRP may be an ideal environment for
proliferation and maturation of articular chondrocytes50. MACT
with PRP can improve cartilage repair in animal models. The same
group started the clinical application in 81 patients with osteo-
chondral lesions; the American Orthopaedic Foot and Ankle Society
score was improved and expression of col-II and proteoglycan
increased after 4 years51.
Safety of PRP treatment
PRP has antimicrobial effects in vitro30; it inhibits macrophage
proliferation and reduces the inﬂammatory response52. Autologous
PRP was found safe for treating knee, foot and ankle lesions in 634
patients53 and for articular cartilage degeneration54. No side effects
have been reported. In 261 patients, no adverse effects were found
following injection of PRP-ﬁbrin glue into the knee joint at 6
months55.
Many studies have suggested safety, pain relief, and functional
improvements with PRP injections for OA; adverse effects are rare
risks, and beneﬁts have been thoroughly reviewed. Risks and
beneﬁts are similar to any other intra-articular or peri-articular
injection; adverse effects include infection, bleeding, bruising, pe-
ripheral nerve injury, allergy to local anesthetics, and temporary
exacerbation of stiffness and soreness that may last from 2 to 7
days56.
Conclusions
Platelet products such as PRP, HPL and platelet supernatants,
which can be activated by endogenous or exogenous activators,
have high efﬁciency and multiple functions. Because of the autog-
enous source, PRP is easy and convenient to extract, and processing
is relatively simple and short; it features high-speed recovery po-
tential, easy handling and offers multiple GFs at relatively inex-
pensive cost. Above all, its use is safe.
Basic science, preclinical, and clinical studies collectively indi-
cate that PRP is promising for treating cartilage injuries and joint
pain. PRP in a culture environment has an anabolic effect on
chondrocytes and bone-marrow derived stem cells with resulting
increases in cell proliferation and matrix production as well as an
anti-inﬂammatory effect via downregulation of known catabolic
signaling pathways. It may be a feasible, secure, and economic way
to induce MSC differentiation into chondrocytes integrally and
expand cartilage cells in vitro. It is a more economic and effective
culture medium substitute for FBS. When added on scaffolds of
cartilage tissue-engineered constructs, it can enhance the regen-
eration of cartilage cells and repair CDs. The application of PRP for
OA in clinical trials has shown promising short-term results (1e2
years), although most of these studies were not randomized
controlled trials.However, challenges remain (Table IV). First, platelet quality
inﬂuences effectiveness, including platelet content, leukocytes and
GF concentration, because preparations of PRP have no selection
criterion. Platelet count in PRP may vary from two- to several-fold
depending on the donor’s physical condition, age or gender, which
leads to unstable and non-repeatable PRP treatment. Some of the
GFs present in PRP such as TGF-beta and bFGF have negative effects
on the OA joint which differ from effects in more normal joints.
Because of multifunctional GF effects, chondrogenesis of MSCs or
chondrocytes expanded in vitro may not retain the chondrocyte
phenotype, such as expression of Col-I instead of type II, simulta-
neous hypertrophy and bone marker expression. So directed
stimulation of GFs might be considered in MSCs and chondrocyte
culture to maintain the chondrocyte phenotype. When several GFs
exist simultaneously, it might inhibit chondrogenesis effect, such as
VEGF and bone morphogenetic protein 2. Impairing osteogenesis
by PRP via mutual cooperationwith other biological molecules may
provide new ways that are prompt, stable, and controllable for
maintaining cartilage morphologic features or to promote chon-
drogenic differentiation.
Second, with the wide range of methodologies used in each
study and the numerous ways to prepare PRP, we cannot provide
ﬁrm recommendations regarding the type of PRP to use and for
what indications. Themethods of platelet application include liquid
injection, PRP gel and bonding with bio-scaffolds. Obviously, with
liquid injection, the required mechanical environment of cartilage
formation is difﬁcult to achieve; moreover, implanted scaffoldsmay
incur unexpected risk and lack integration. The roles for the
respective treatment regimens still need to be deﬁned, because
many of the questions concerning PRP mechanisms of action
remain unanswered.
Future directions of PRP application in OA therapy may
concentrate on seeking an appropriate and innocuous agent like
anti-VEGF antibody that can modulate and control the effect of PRP
by biological integration, when blocking VEGF, defects were
repaired mostly with hyaline cartilage57.
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